Gliomas, tumors that originate from glial cells (e.g., astrocytes, oligodendrocytes), are the most common group of primary brain tumors with an estimated incidence in the USA of ~18,500 new cases per year. Patients with glioblastoma multiforme (GBM), the most malignant and lethal astrocytic tumor, have a poor prognosis, with a median survival of ~1 year. Malignant glioma cells are highly invasive and their efficient infiltration into adjacent normal brain tissue prevents complete surgical removal or effective destruction by lethal radiation exposure. The Fn14 gene, initially discovered in our laboratory during a screen for growth factor-inducible genes in murine fibroblasts, encodes a cell surface receptor for the multifunctional cytokine tumor necrosis factor-like weak inducer of apoptosis (TWEAK). We have found that Fn14 gene expression is frequently elevated in glioma cells located in both the tumor core and invasive rim regions of GBM specimens. We have also shown that Fn14 overexpression in transfected cells activates the nuclear factor (NF)-kB signaling pathway. We hypothesize that Fn14 overexpression in glioma cells promotes constitutive, ligand-independent activation of the NF-kB signaling pathway, and that the hyperactivation of this pathway contributes to glioma cell invasiveness in vivo. In addition, we hypothesize that the Fn14 cell surface receptor may be a novel target for ligand:cytotoxin fusion protein-based brain tumor therapy. Accordingly, the Specific Aims of this proposal are:(1) To determine whether Fn14 overexpression in transfected human glioma cell lines stimulates NF-kB activation, cell proliferation, cell migration, matrix metalloproteinase production or cell invasion in vitro, (2) To determine whether Fn14 overexpression in transfected human glioma cell lines stimulates cell invasion ex vivo or in vivo, (3) To determine whether NF-kB activation is critical for Fn14-mediated glioma cell invasion, and (4) To determine whether aTWEAK-Pseudomonas exotoxin fusion protein is cytotoxic to Fn14-positive glioma cells. Relevance to public health: Many brain tumors are highly invasive and consequently very difficult to treat. The proposed studies will examine whether a protein named Fn14 contributes to tumor cell invasiveness and whether it could be a novel molecular target for anti-invasive therapy in humans.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS055126-04
Application #
7738478
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Fountain, Jane W
Project Start
2007-01-19
Project End
2011-11-30
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
4
Fiscal Year
2010
Total Cost
$321,596
Indirect Cost
Name
University of Maryland Baltimore
Department
Surgery
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Zhou, Hong; Mohamedali, Khalid A; Gonzalez-Angulo, Ana Maria et al. (2014) Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC. Mol Cancer Ther 13:2688-705
Gurunathan, Sujatha; Winkles, Jeffrey A; Ghosh, Sankar et al. (2014) Regulation of fibroblast growth factor-inducible 14 (Fn14) expression levels via ligand-independent lysosomal degradation. J Biol Chem 289:12976-88
Dhruv, Harshil D; Whitsett, Timothy G; Jameson, Nathan M et al. (2014) Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation. Carcinogenesis 35:218-26
Zhou, Hong; Hittelman, Walter N; Yagita, Hideo et al. (2013) Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. Cancer Res 73:4439-50
Cheng, Emily; Armstrong, Cheryl L; Galisteo, Rebeca et al. (2013) TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic. Front Immunol 4:473
Brown, Sharron A N; Cheng, Emily; Williams, Mark S et al. (2013) TWEAK-independent Fn14 self-association and NF-?B activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain. PLoS One 8:e65248
Zhou, Hong; Ekmekcioglu, Suhendan; Marks, John W et al. (2013) The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol 133:1052-62
Fortin, Shannon P; Ennis, Matthew J; Schumacher, Cassie A et al. (2012) Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cells. Mol Cancer Res 10:958-68
Whitsett, Timothy G; Cheng, Emily; Inge, Landon et al. (2012) Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol 181:111-20
Ranganathan, Sripriya; Noyes, Nathaniel C; Migliorini, Mary et al. (2011) LRAD3, a novel low-density lipoprotein receptor family member that modulates amyloid precursor protein trafficking. J Neurosci 31:10836-46

Showing the most recent 10 out of 14 publications